Table 1.

Baseline demographics, medical history, medication use, and laboratory values for the EVOLVE study participants

DemographicCinacalcet Group
(n=1948)Placebo Group
(n=1935)
Age (yr)55.0 (35.0, 74.0)54.0 (35.0, 73.0)
Women41.539.7
Body mass index (kg2/m2)26.3 (20.4, 36.4)26.4 (20.6, 36.7)
Region
 Australia3.83.9
 Canada3.73.8
 Europe30.730.5
 Latin America17.717.7
 Russia7.37.2
 United States36.737.0
Race
 Black21.022.1
 White57.757.7
 Other21.320.2
Medical history
 Dialysis vintage (mo)45.4 (8.5, 142.0)45.1 (9.8, 149.6)
 Tobacco use
  Never55.756.7
  Former28.126.7
  Current16.016.5
 Proton pump inhibitor use 30.228.6
 Vitamin D use59.359.6
 Hormone replacement therapy7.77.3
 Calcium-containing phosphate binder use53.253.0
 Alcohol use16.918.6
Laboratory parameters
 Serum albumin (g/dl)3.7 (3.2, 4.1)3.7 (3.2, 4.1)
 Serum BALP (ng/ml)23.1 (11.5, 71.0)22.9 (11.5, 66.6)
 Serum calcium (mg/dl)9.8 (9.0, 10.7)9.8 (9.0, 10.7)
 Plasma intact PTH (pg/ml)694.5 (362.0, 1707.0)690.0 (363.0, 1683.0)
 Serum phosphorus (mg/dl)6.3 (4.9, 8.3)6.2 (4.9, 8.4)
 Serum 25-hydroxy cholecalciferol (µg/L)17.0 (8.0, 37.0)18.0 (8.0, 38.0)
  • Data are presented as a percentage or median (10th percentile, 90th percentile). Adapted from Chertow et al.20